Investments
42Portfolio Exits
5Funds
1About Seroba Life Sciences
Seroba Life Sciences, fka Seroba Kernel Life Sciences, is a European venture capital firm that invests across the spectrum of the life science industry including medical devices, biotechnology, specialty pharmaceuticals, therapeutic drugs, medical technology, diagnostics, instrumentation, and other selected opportunities. Seroba funds new healthcare opportunities through key value-adding stages, from inception through development and clinical evaluation, the generation of intellectual property, regulatory approvals and market launch, and partnering pharmaceutical or medtech companies.
Want to inform investors similar to Seroba Life Sciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Seroba Life Sciences News
Jan 25, 2023
Deciphex , a Dublin, Ireland-based provider of pathology software and services, raised €3.9M in funding. The round was led by Seroba Life Sciences and existing investors. Jennifer McMahon, a partner with Seroba, will join the Board of Deciphex. The company intends to use the funds to continue developing its products and services, to expand its presence in the UK, Canada, the Middle East and the US, and to strengthen its position in the field of digital pathology and AI. Led by CEO Donal O’Shea, Deciphex offers a range of services for clinical and research pathology, including its Patholytix platform for research pathology. Its Diagnostics as a service platform, Diagnexia, connects laboratories to an international network of subspeciality pathologists, who can provide their expertise on clinical cases, while reducing turnaround times and ensuring the delivery of the highest quality of patient care. Commenting on the news, Donal O’Shea said: “This additional investment will allow us to continue to grow and innovate, solidifying our position as a leader in the field of pathology. We are committed to helping pathologists deliver the best possible care to patients through the use of cutting-edge technology.“ FinSMEs
Seroba Life Sciences Investments
42 Investments
Seroba Life Sciences has made 42 investments. Their latest investment was in Deciphex as part of their Series B - II on January 1, 2023.
Seroba Life Sciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
1/23/2023 | Series B - II | Deciphex | $4.24M | Yes | Seroba Life Sciences, and Undisclosed Investors | 7 |
12/14/2022 | Series B | STORM Therapeutics | $30M | No | 6 | |
10/4/2022 | Series A | Sibylla Biotech | $22.68M | Yes | 8 | |
2/9/2022 | Series A | |||||
1/20/2022 | Series C |
Date | 1/23/2023 | 12/14/2022 | 10/4/2022 | 2/9/2022 | 1/20/2022 |
|---|---|---|---|---|---|
Round | Series B - II | Series B | Series A | Series A | Series C |
Company | Deciphex | STORM Therapeutics | Sibylla Biotech | ||
Amount | $4.24M | $30M | $22.68M | ||
New? | Yes | No | Yes | ||
Co-Investors | Seroba Life Sciences, and Undisclosed Investors | ||||
Sources | 7 | 6 | 8 |
Seroba Life Sciences Portfolio Exits
5 Portfolio Exits
Seroba Life Sciences has 5 portfolio exits. Their latest portfolio exit was PQ Bypass on April 13, 2021.
Seroba Life Sciences Fund History
1 Fund History
Seroba Life Sciences has 1 fund, including Seroba Life Sciences Fund III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
2/2/2017 | Seroba Life Sciences Fund III | $108.08M | 3 |
Closing Date | 2/2/2017 |
|---|---|
Fund | Seroba Life Sciences Fund III |
Fund Type | |
Status | |
Amount | $108.08M |
Sources | 3 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.